Anticorps Polyclonal de lapin anti-C3/C3b/C3c

• Phare
• Validé par KD/KO

C3/C3b/C3c Polyclonal Antibody for WB, IHC, IF/ICC, IF-P, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat et plus (3)

Applications

WB, IHC, IF/ICC, IF-P, IP, CoIP, ELISA

Conjugaison

Non conjugué

Publications(109)

Avis (3)

N° de cat : 21337-1-AP

Synonymes

C3, C3/C3a, Acylation stimulating protein, ARMD9, ASP

---

Galerie de données de validation

• 

  WB analysis of human plasma using 21337-1-AP

  human plasma was subjected to SDS PAGE followed by western blot with 21337-1-AP (C3/C3b/C3c antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of rat plasma using 21337-1-AP

  rat plasma was subjected to SDS PAGE followed by western blot with 21337-1-AP (C3/C3b/C3c antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of human plasma using 21337-1-AP

  IP result of anti-C3/C3b/C3c (IP:21337-1-AP, 4ug; Detection:21337-1-AP 1:1000) with human plasma lysate 4000 ug.

• 

  IHC staining of human liver using 21337-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver tissue slide using 21337-1-AP (C3/C3b/C3c antibody) at dilution of 1:2000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver using 21337-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver tissue slide using 21337-1-AP (C3/C3b/C3c antibody) at dilution of 1:2000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver cancer using 21337-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 21337-1-AP (C3/C3b/C3c antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver cancer using 21337-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 21337-1-AP (C3/C3b/C3c antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of human liver cancer using 21337-1-AP

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using C3/C3b/C3c antibody (21337-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

• 

  IF Staining of human liver cancer using 21337-1-AP

  Immunofluorescent analysis of (4% PFA) fixed human liver cancer tissue using C3/C3b/C3c antibody (21337-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

• 

  IF Staining of HepG2 using 21337-1-AP

  Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using C3/C3b/C3c antibody (21337-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2).

---

Applications testées

• Résultats positifs en WB: rat plasma, plasma humain
• Résultats positifs en IP: tissu plasmatique humain
• Résultats positifs en IHC: tissu hépatique humain, tissu de cancer du foie humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF-P: tissu de cancer du foie humain,
• Résultats positifs en IF/ICC: cellules HepG2,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:1000-1:4000
• Immunofluorescence (IF)-P: IF-P : 1:50-1:500
• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 3 publications below
• WB: See 66 publications below
• IHC: See 15 publications below
• IF: See 54 publications below
• CoIP: See 1 publications below

Informations sur le produit

21337-1-AP cible C3/C3b/C3c dans les applications de WB, IHC, IF/ICC, IF-P, IP, CoIP, ELISA et montre une réactivité avec des échantillons Humain, rat

• Réactivité: Humain, rat
• Réactivité citée: rat, bovin, Humain, porc, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: C3/C3b/C3c Protéine recombinante Ag15537
• Nom complet: complement component 3
• Masse moléculaire calculée: 1663 aa, 187 kDa
• Poids moléculaire observé: 115 kDa
• Numéro d’acquisition GenBank: BC150179
• Symbole du gène: C3
• Identification du gène (NCBI): 718
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

The complement system is an important effector that bridges the innate and adaptive immune systems (PMID: 20010915). The third component of complement, C3, plays a central role in activating the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways (PMID: 11414361). Human C3 (190-195 kDa), composed of α and β chains (115-120 and 75 kDa, respectively), is cleaved into C3a and C3b by C3 convertase. C3b is composed of the α' chain and β chain (PMID: 27210597). Factor I cleaves the α′ chain of C3b to 68 kDa and 43 kDa degradation products (iC3b) (PMID: 25395424; 14527961). This antibody raised against 1314-1663 aa of human C3 protein recognizes the C3 α chain (115-120 kDa), C3b α' chain (110-115 kDa), and C3c α' chain fragment 2 (43 kDa).

Publications

Species	Application	Title
mouse	WB	Nat Cell Biol; Autophagy enables microglia to engage amyloid plaques and prevents microglial senescence; Authors - Insup Choi
mouse	WB	Brain Behav Immun; PDE4 inhibition alleviates HMGB1/C1q/C3-mediated excessive phagocytic pruning of synapses by microglia and depressive-like behaviors in mice; Authors - Qian Zhao
		Brain; Extracellular vesicle biomarkers for complement dysfunction in schizophrenia; Authors - Ting Xue
	IF	J Autoimmun; TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation; Authors - Junpeng Zhao
mouse	IHC,IF	Gut Microbes; Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression; Authors - Ran Zhang
human	IHC	Nat Commun; Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration.; Authors - Valentina Cipriani

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.

---

FH

Boyan (Verified Customer) (08-27-2025)

good for WB, two bands at ~190 and 130 kd, both of which are C3 forms

• Applications: Western Blot
• Cell Tissue Type: human

FH

Marisa (Verified Customer) (07-31-2025)

We used the C3/C3b/C3c antibody in immunofluorescence and obtained a detectable signal, though some background was present. With slight optimization, it worked for visualizing complement activation by confocal microscopy.

• Applications: Immunofluorescence
• Primary Antibody Dilution: 1/100
• Cell Tissue Type: Brain

C3/C3b/C3c Antibody Immunofluorescence validation (1/100 dilution) in Brain (Cat no:21337-1-AP)

FH

Marion (Verified Customer) (08-01-2024)

LPS induction model Fixative : Paraformaldehyde 4% Permeabilization: 10 min; RT; 0.2% Triton X-100 Blocking: 2 h; RT; 10% Normal donkey serum; 1% BSA Primary antibody: 1 night; 4°C Secondary antibody: ab150064 (Abcam); 1h30; RT Antibodies diluted in blocking solution

• Applications: Immunofluorescence
• Primary Antibody Dilution: 1/200
• Cell Tissue Type: Rat Kidney

C3/C3b/C3c Antibody Immunofluorescence validation (1/200 dilution) in Rat Kidney (Cat no:21337-1-AP)

{{ptg:RelatedPrimaryAntibodies}}